P4_unuppsala

Uppsala University
Rudbeck Laboratory


Scientists in charge

Anna Dimberg
Anna Dimberg
I am an Associate Professor and group leader in the department of Immunology, Genetics and Pathology at Uppsala University with a focus on tumor vascular biology. My main interest is the molecular regulation of tumor angiogenesis and the role of the vasculature in shaping the tumor microenvironment. In my group, we have successfully characterized the gene expression profile of human glioblastoma vessels as compared to vessels in normal brain and low grade glioma. We are currently investigating how differential gene expression in the tumor vessels affect glioblastoma progression to find new targets for therapy. Another focus in the group is to investigate cross-talk between pro-angiogenic and pro-inflammatory signaling pathways to understand regulation of endothelial activation and leukocyte recruitments in tumors, and to explore vascular normalization therapies to improve immunotherapy of cancer. I am an author of 36 scientific publications in high-ranking journals including Blood, Nature Communications, EMBO journal, Journal of Pathology, Nature Reviews Cell Biology and FASEB journal.

 

Website

Publications Anna Dimberg
Sara Mangsbo
Sara Mangsbo
I am a co-group leader together with Professor Tötterman at the department of Immunology Genetics and Pathology, Uppsala University (www.uu.se). I am is also the Founder and CEO of the newly formed biotechnology company Immuneed AB that focuses on the development of a novel vaccine strategy utilizing immune complexes as a delivery tool of long synthetic peptides for tumor immunotherapy (www.immuneed.com).
My group focuses on the development of new immunotherapies for the treatment of solid tumors. Recently our group together with Alligator Bioscience AB published our work around the development of an agonistic anti-CD40 antibody (ADC-1013) for local immunotherapy in the journal of Clinical Cancer Research. In 2013 Dr Mangsbo received a grant from BIO-X/Vinnova to take the peptide conjugate vaccine (immune-complex based vaccine) towards a clinical trial. The development of the vaccine is performed in collaboration with LUMC and Dr Drijfhout/ Professor Ossendorp as well as Immuneed AB. I am is the author of 22 peer-reviewed articles and has supervised three now dissertated doctors and is currently supervising another five PhD students. In 2014Ie was awarded the Göran Gustafsson prize to young researchers.

 

Website

Publications Sara Mangsbo

 

Appointed Researchers

Maria Georganaki
Early Stage Researcher: Maria Georganaki (Greece)
Appointed from 1 July 2013 till 1 July 2016

 

 

 

Luuk van Hooren
Early Stage Researcher: Luuk van Hooren (The Netherlands)
Appointed from 1 August 2013 till 1 August 2016